Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Humanigen Inc (HGEN)

Humanigen Inc (HGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 24
  • Shares Outstanding, K 119,080
  • Annual Sales, $ 2,510 K
  • Annual Income, $ -70,730 K
  • 60-Month Beta -1.04
  • Price/Sales 2.18
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HGEN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.66
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 01/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 +100.00%
on 01/04/24
0.0050 -96.00%
on 12/26/23
-0.0048 (-96.00%)
since 12/04/23
3-Month
0.0001 +100.00%
on 01/04/24
0.0149 -98.66%
on 10/12/23
-0.0141 (-98.60%)
since 10/04/23
52-Week
0.0001 +100.00%
on 01/04/24
0.2390 -99.92%
on 02/07/23
-0.1698 (-99.88%)
since 01/04/23

Most Recent Stories

More News
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk...

HGEN : 0.0002 (-84.62%)
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously...

HGEN : 0.0002 (-84.62%)
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

CRSP : 55.65 (-1.35%)
HGEN : 0.0002 (-84.62%)
KALA : 6.40 (-2.53%)
ALLO : 3.04 (-9.79%)
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix...

HGEN : 0.0002 (-84.62%)
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RAPT : 7.90 (-1.25%)
HGEN : 0.0002 (-84.62%)
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 2.75 (unch)
HGEN : 0.0002 (-84.62%)
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

LQDA : 12.55 (-3.09%)
HGEN : 0.0002 (-84.62%)
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VRTX : 400.76 (-1.02%)
HGEN : 0.0002 (-84.62%)
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Humanigen, Inc. (HGEN) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and...

HGEN : 0.0002 (-84.62%)
HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging...

HGEN : 0.0002 (-84.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Humanigen, Inc. is a biopharmaceutical company. It focuses on advancing medicines for patients with neglected and rare diseases. The Company's product candidate principally consists of benznidazole, lenzilumab and ifabotuzumab. Humanigen Inc., formerly known as KaloBios Pharmaceuticals Inc., is based...

See More

Key Turning Points

3rd Resistance Point 0.0008
2nd Resistance Point 0.0007
1st Resistance Point 0.0004
Last Price 0.0002
1st Support Level 0.0000
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.2390
Fibonacci 61.8% 0.1477
Fibonacci 50% 0.1195
Fibonacci 38.2% 0.0914
Last Price 0.0002
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar